BlackRock
LXEO icon

BlackRock’s Lexeo Therapeutics LXEO Stock Holding History

BlackRock’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.7M Buy
5,739,455
+628,584
+12% +$3.4M ﹤0.01% 3076
2026
Q1 		$29.3M Buy
5,110,871
+203,308
+4% +$1.44M ﹤0.01% 2840
2025
Q4 		$48.7M Buy
4,907,563
+2,736,471
+126% +$25M ﹤0.01% 2532
2025
Q3 		$14.4M Buy
2,171,092
+343,128
+19% +$1.66M ﹤0.01% 3269
2025
Q2 		$7.35M Sell
1,827,964
-14,268
-0.8% -$46.9K ﹤0.01% 3569
2025
Q1 		$6.39M Buy
1,842,232
+20,266
+1% +$89.8K ﹤0.01% 3534
2024
Q4 		$12M Buy
1,821,966
+191,679
+12% +$1.51M ﹤0.01% 3334
2024
Q3 		$14.7M Buy
1,630,287
+838,703
+106% +$10M ﹤0.01% 3214
2024
Q2 		$12.7M Buy
791,584
+128,622
+19% +$1.87M ﹤0.01% 3243
2024
Q1 		$10.4M Buy
662,962
+493,066
+290% +$7.71M ﹤0.01% 3334
2023
Q4 		$2.28M Buy
+169,896
New +$2.11M ﹤0.01% 3995

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BlackRock's LXEO Position: Q2 2026 in Review

BlackRock increased its Lexeo Therapeutics (LXEO) stake by 12% in Q2 2026, buying an estimated $3.4M and bringing the position to 5,739,455 shares worth $26.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3076.

BlackRock first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $48.7M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • BlackRock held 5,739,455 shares of Lexeo Therapeutics worth $26.7M as of Q2 2026.
  • BlackRock bought 628,584 Lexeo Therapeutics shares in Q2 2026, an estimated $3.4M.
  • Lexeo Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3076 holding.
  • BlackRock first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • BlackRock's Lexeo Therapeutics position peaked at $48.7M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.